{"id":"NCT01507831","sponsor":"Sanofi","briefTitle":"Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)","officialTitle":"Long-term Safety and Tolerability of SAR236553 (REGN727) in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid Modifying Therapy: A Randomized, Double-Blind, Placebo-Controlled Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-01","primaryCompletion":"2014-11","completion":"2014-11","firstPosted":"2012-01-11","resultsPosted":"2015-12-22","lastUpdate":"2015-12-22"},"enrollment":2341,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypercholesterolemia"],"interventions":[{"type":"DRUG","name":"Placebo (for alirocumab)","otherNames":[]},{"type":"DRUG","name":"Alirocumab","otherNames":["SAR236553","REGN727","Praluent"]},{"type":"DRUG","name":"Lipid-Modifying Therapy (LMT)","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Alirocumab","type":"EXPERIMENTAL"}],"summary":"Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9).\n\nPrimary Objective of the study:\n\nTo evaluate the long-term safety and tolerability of alirocumab in high cardiovascular risk participants with hypercholesterolemia not adequately controlled with their current lipid modifying therapy (LMT).\n\nSecondary Objectives:\n\n* To evaluate the effect of alirocumab on low-density lipoprotein cholesterol (LDL-C) levels after 24 weeks of treatment in comparison with placebo.\n* To evaluate the effect of alirocumab in comparison with placebo on LDL-C at other time points.\n* To evaluate the effects of alirocumab on other lipid parameters.","primaryOutcome":{"measure":"Percentage of Participants Who Experienced Adverse Events (AEs)","timeFrame":"Up to 10 weeks after last study drug administration (maximum of 86 weeks)","effectByArm":[{"arm":"Placebo Q2W","deltaMin":82.5,"sd":null},{"arm":"Alirocumab 150 mg Q2W","deltaMin":81,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":3},"locations":{"siteCount":320,"countries":["United States","Argentina","Belgium","Bulgaria","Canada","Chile","Colombia","Czechia","Denmark","Finland","France","Germany","Hungary","Israel","Italy","Mexico","Netherlands","Norway","Poland","Portugal","Romania","Russia","South Africa","Spain","Sweden","Ukraine","United Kingdom"]},"refs":{"pmids":["25773378","34298554","30183102","28964736","28391886","27777279"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":154,"n":788},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Urinary tract infection","Back pain","Diarrhoea"]}}